Seroepidemiology of mumps in Europe (1996-2008): why do outbreaks occur in highly vaccinated populations?

Mumps outbreaks have recently been recorded in a number of highly vaccinated populations. We related seroprevalence, epidemiological and vaccination data from 18 European countries participating in The European Sero-Epidemiology Network (ESEN) to their risk of mumps outbreaks in order to inform vacc...

ver descrição completa

Detalhes bibliográficos
Autores: Eriksen, J, Davidkin, I, Kafatos, G, Andrews, N, Barbara, C, Cohen, D, Duks, A, Griškevičius, A, Johansen, K, Bartha, K, Kriz, B, Mitis, G, Mossong, J, Nardone, A, O'Flanagan, D, De Ory, Fernando de, Pistol, A, Theeten, H, Prosenc, K, Slacikova, M, Pebody, Richard
Formato: artículo
Fecha de publicación:2013
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/11498
Acesso em linha:http://hdl.handle.net/20.500.12105/11498
Access Level:acceso abierto
Palavra-chave:Disease Outbreaks
Mumps Vaccine
Adolescent
Adult
Antibodies, Viral
Child
Child, Preschool
Europe
Female
Humans
Immunization Schedule
Incidence
Infant
Male
Middle Aged
Mumps
Mumps virus
Seroepidemiologic Studies
Vaccination
Young Adult
Descrição
Resumo:Mumps outbreaks have recently been recorded in a number of highly vaccinated populations. We related seroprevalence, epidemiological and vaccination data from 18 European countries participating in The European Sero-Epidemiology Network (ESEN) to their risk of mumps outbreaks in order to inform vaccination strategies. Samples from national population serum banks were collected, tested for mumps IgG antibodies and standardized for international comparisons. A comparative analysis between countries was undertaken using age-specific mumps seroprevalence data and information on reported mumps incidence, vaccine strains, vaccination programmes and vaccine coverage 5-12 years after sera collection. Mean geometric mumps antibody titres were lower in mumps outbreak countries [odds ratio (OR) 0·09, 95% confidence interval (CI) 0·01-0·71)]. MMR1 vaccine coverage ⩾95% remained protective in a multivariable model (P < 0·001), as did an interval of 4-8 years between doses (OR 0·08, 95% CI 0·01-0·85). Preventing outbreaks and controlling mumps probably requires several elements, including high-coverage vaccination programmes with MMR vaccine with 4-8 years between doses.

Registos relacionados